KR20230037612A - Il-2 변이체 - Google Patents
Il-2 변이체 Download PDFInfo
- Publication number
- KR20230037612A KR20230037612A KR1020237004667A KR20237004667A KR20230037612A KR 20230037612 A KR20230037612 A KR 20230037612A KR 1020237004667 A KR1020237004667 A KR 1020237004667A KR 20237004667 A KR20237004667 A KR 20237004667A KR 20230037612 A KR20230037612 A KR 20230037612A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- cancer
- protein
- reduction
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063050068P | 2020-07-09 | 2020-07-09 | |
| US63/050,068 | 2020-07-09 | ||
| PCT/IB2021/056106 WO2022009123A1 (en) | 2020-07-09 | 2021-07-07 | Il-2 variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230037612A true KR20230037612A (ko) | 2023-03-16 |
Family
ID=79552299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237004667A Pending KR20230037612A (ko) | 2020-07-09 | 2021-07-07 | Il-2 변이체 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230242607A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4185605A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7819944B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230037612A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115768788A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022009123A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022053864A1 (en) * | 2020-09-08 | 2022-03-17 | Kwon Byoung S | Pd-1 polypeptide variants |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CN114853909A (zh) * | 2022-05-13 | 2022-08-05 | 南京吉盛澳玛生物医药有限公司 | 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088446A1 (en) * | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| CN105440123B (zh) * | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| JP6640834B2 (ja) * | 2014-08-11 | 2020-02-05 | デリニア, インコーポレイテッド | 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体 |
| WO2016100375A2 (en) * | 2014-12-15 | 2016-06-23 | Washington University | Compositions and methods for targeted cytokine delivery |
| AU2018287317B2 (en) * | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
| JP7765181B2 (ja) * | 2017-12-19 | 2025-11-06 | ゼンコア インコーポレイテッド | 改変されたil-2 fc融合タンパク質 |
| CU24554B1 (es) * | 2018-05-07 | 2021-11-04 | Ct Inmunologia Molecular | Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 |
| WO2019239213A2 (en) | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| US12522640B2 (en) * | 2018-07-24 | 2026-01-13 | BioNTech SE | IL2 agonists |
| CA3098930A1 (en) * | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| CN113286812B (zh) * | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| CA3117853A1 (en) * | 2018-10-29 | 2020-05-07 | 1Globe Biomedical Co., Ltd. | Novel rationally designed protein compositions |
| AU2020285636A1 (en) * | 2019-05-24 | 2021-11-04 | Proviva Therapeutics (Hong Kong) Limited | IL-2 compositions and methods of use thereof |
| EP4172216A4 (en) * | 2020-06-24 | 2024-12-04 | Medicenna Therapeutics, Inc. | BIFUNCTIONAL SUPERKINE AND USES THEREOF |
| IL304365B2 (en) * | 2021-03-31 | 2025-04-01 | Hanmi Pharmaceutical Co Ltd | A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof |
-
2021
- 2021-07-07 JP JP2023501378A patent/JP7819944B2/ja active Active
- 2021-07-07 KR KR1020237004667A patent/KR20230037612A/ko active Pending
- 2021-07-07 EP EP21837391.8A patent/EP4185605A4/en active Pending
- 2021-07-07 US US18/004,575 patent/US20230242607A1/en not_active Abandoned
- 2021-07-07 CN CN202180048794.7A patent/CN115768788A/zh active Pending
- 2021-07-07 WO PCT/IB2021/056106 patent/WO2022009123A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN115768788A (zh) | 2023-03-07 |
| JP7819944B2 (ja) | 2026-02-25 |
| EP4185605A4 (en) | 2024-07-17 |
| WO2022009123A1 (en) | 2022-01-13 |
| JP2023534793A (ja) | 2023-08-14 |
| EP4185605A1 (en) | 2023-05-31 |
| WO2022009123A4 (en) | 2022-02-24 |
| US20230242607A1 (en) | 2023-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7724254B2 (ja) | バイアス型il2ムテイン、方法、および組成物 | |
| US20230272033A1 (en) | Epha3 and multi-valent targeting of tumors | |
| US11905334B2 (en) | Anti-human VSIG4 antibodies and uses thereof | |
| JP7819944B2 (ja) | Il-2バリアント | |
| JP2025098135A (ja) | Pd-1ポリペプチド変異体 | |
| US12122845B2 (en) | Anti-HER2/anti-4-1BB bispecific antibodies and uses thereof | |
| WO2024046322A9 (en) | Agonistic interleukin 15 complexes and uses thereof | |
| KR20220155589A (ko) | Il-18을 분비하는 gpc3 car-t 세포 및 이의 제조 및 사용 방법 | |
| CA2930243C (en) | Epha3 and multi-valent targeting of tumors | |
| HK40084424A (en) | Gpc3 car- t cells secreting il-18 and methods of making and using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| D13-X000 | Search requested |
St.27 status event code: A-1-2-D10-D13-srh-X000 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |